Journal article
Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development
M Bialer, SI Johannessen, MJ Koepp, RH Levy, E Perucca, P Perucca, T Tomson, HS White
Epilepsia | WILEY | Published : 2020
DOI: 10.1111/epi.16726
Abstract
The Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV) was held as a fully virtual conference from July 27 to July 30, 2020 for the sessions on drugs, and on August 3, 2020 for the sessions on devices. A total of 534 delegates from 63 countries attended lectures and interactive discussions, representing a broad range of disciplines from basic science, clinical research, and clinical care. This progress report provides summaries of recent findings on investigational compounds for which preclinical data as well as data from patient studies were presented. The report includes the following five compounds: anakinra, cenobamate, CVL-865, fenfluramine, and ganaxolone, all..
View full abstractGrants
Awarded by Epilepsy Foundation
Funding Acknowledgements
We wish to thank the authors of the summary sections for their patience in addressing the queries raised during the review process, and for their collaboration with the final editing of the manuscript. For the section on cenobamate, medical writing support to the summary authors was provided by Leonard Lionnet (Lev Medical Communications). Edward Weselcouch, funded by Zogenix, provided professional medical writing assistance to the summary authors in the preparation of the section on fenfluramine.